SCHEMBL525525

SCHEMBL525525

O=C(O)Cc1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.59
MAPT P10636 2/20 0.57
FFAR1 O14842 7/20 0.56
PPARA Q07869 2/20 0.56
CYP3A4 P08684 2/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HRH3 Q9Y5N1 1/20 0.51
MPC2 O95563 2/20 0.50
CYP2C8 P10632 2/20 0.50
CYP2C9 P11712 2/20 0.50
RXRA P19793 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583787 0.99 PPARG (0.58) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL8312939 0.90 MAPT (0.69) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3592956 0.88 CA2 (0.60) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3589714 0.88 MAPT (0.59) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3583789 0.88 MAPT (0.56) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3594379 0.86 PPARG (0.48) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3602711 0.86 CA2 (0.49) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3587657 0.86 PPARG (0.51) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3593803 0.86 PPARG (0.54) PPARGMAPTFFAR1PPARACYP3A4
SCHEMBL3589923 0.85 ALDH1A1 (0.56) PPARGMAPTFFAR1PPARAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2987488-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LUNG DISORDERS Orchid Chemicals and Pharmaceuticals Ltd (IN) 2016-02-24 EP claimed
EP-2598142-B1 DIPHENYL ETHER COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISORDERS ORCHID CHEMICALS & PHARM LTD (IN) 2015-12-16 EP claimed
US-20140187594-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) 2014-07-03 US claimed
EP-2004185-B1 NOVEL HETEROCYCLIC DIPHENYL ETHERS BEXEL PHARMACEUTICALS INC (US) 2013-06-26 EP claimed
EP-2598142-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES Orchid Chemicals and Pharmaceuticals Ltd (IN) 2013-06-05 EP claimed
WO-2012014218-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES ORCHID RESEARCH LABORATORIES LTD. (IN) 2012-02-02 WO claimed
US-7781464-B2 Heterocyclic diphenyl ethers BEXEL PHARMACEUTICALS, INC. (US) 2010-08-24 US claimed
EP-2004185-A2 NOVEL HETEROCYCLIC DIPHENYL ETHERS Bexel Pharmaceuticals Inc (US) 2008-12-24 EP claimed
WO-2007097992-A2 NOVEL HETEROCYCLIC DIPHENYL ETHERS BEXEL PHARMACEUTICALS, INC. (US) 2007-08-30 WO claimed
US-20060247285-A1 Novel heterocyclic diphenyl ethers BEXEL PHARMACEUTICALS, INC. 2006-11-02 US claimed
EP-2987488-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LUNG DISORDERS Orchid Chemicals and Pharmaceuticals Ltd (IN) 2016-02-24 EP disclosed
EP-2598142-B1 DIPHENYL ETHER COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISORDERS ORCHID CHEMICALS & PHARM LTD (IN) 2015-12-16 EP disclosed
US-20140187594-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) 2014-07-03 US disclosed
US-20140187594-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) 2014-07-03 US disclosed
US-20140187594-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) 2014-07-03 US disclosed
US-7781464-B2 Heterocyclic diphenyl ethers BEXEL PHARMACEUTICALS, INC. (US) 2010-08-24 US disclosed
EP-2004185-A2 NOVEL HETEROCYCLIC DIPHENYL ETHERS Bexel Pharmaceuticals Inc (US) 2008-12-24 EP disclosed
WO-2007097992-A2 NOVEL HETEROCYCLIC DIPHENYL ETHERS BEXEL PHARMACEUTICALS, INC. (US) 2007-08-30 WO disclosed
WO-2007097992-A2 NOVEL HETEROCYCLIC DIPHENYL ETHERS BEXEL PHARMACEUTICALS, INC. (US) 2007-08-30 WO disclosed
US-20060247285-A1 Novel heterocyclic diphenyl ethers BEXEL PHARMACEUTICALS, INC. 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247285-A1 Novel heterocyclic diphenyl ethers FFAR4, FFAR3, GPR119 PPARG 12/4885MAPT 318/4885FFAR1 5/4885
US-20140187594-A1 DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES PYGL, CPT1A, GYS2 PPARG 8/4885MAPT 64/4885FFAR1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.